MN SF3125

Requires medical assistance and EPSDT programs to cover routine patient costs incurred during participation in approved clinical trials if the same costs would be covered outside a clinical trial.

Maintains existing prohibition on coverage for costs incidental to, associated with, or resulting from use of investigational drugs, biological products, or devices.

Allows EPSDT coverage of stiripentol for patients with Dravet syndrome or children with malignant migrating partial epilepsy due to SCN2A genetic mutation if FDA approves an individual patient investigational new drug application.

Requires all other available covered prescription medications to be tried without successful outcomes before stiripentol coverage is approved.

Excludes stiripentol coverage provision from MinnesotaCare coverage under chapter 256L.